General Disclosure

General Disclosure of Financial Relationships Between FPA Physicians and Industry

Mount Sinai takes pride in the excellence and expertise of our physicians, and we make every effort to ensure that our physicians’ clinical decisions are made in the best interests of each patient. Often, as leaders in their respective fields, our physicians are highly qualified to collaborate with commercial companies in the development of new and innovative therapies to improve the treatment options for patients. Commercial companies also often support the education and research missions of Mount Sinai by making donations to these programs.

Mount Sinai believes that collaborative relationships with industry are vital to promoting innovations in patient care and treatment, inventing and testing new technology and advancing the continued education of our physicians in these new technologies. At the same time, however, Mount Sinai recognizes that these relationships must be carefully scrutinized to ensure that they do not bias or appear to influence the medical decisions of the institution or its physicians, and we have a vigorous program in place to review and manage such relationships.

It is important to Mount Sinai that you are aware of the potential relationships with industry and that you have the opportunity to ask any questions about such relationships. If you have such questions, we encourage you to discuss them with your physician.

Dr. Adams is the co-inventor of the Edwards Lifesciences' Carpentier-McCarthy-Adams IMR ETlogix Annuloplasty Ring and Carpentier-Edwards Physio II ring. Mount Sinai School of Medicine receives royalties from Edwards Lifesciences in connection with the sale of this product, but does not receive any royalties when the devices are implanted in patients at Mount Sinai.

Dr. Adams is the inventor of the Medtronic Tri-Ad™ Adams Tricuspid Annuloplasty Ring. Mount Sinai School of Medicine receives royalties from Medtronic in connection with the sale of this product, but does not receive any royalties when the device is implanted in patients at Mount Sinai. Dr. Adams is also National Co-Principal Investigator of the FDA Medtronic-CoreValve Pivotal Trial.